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. Additionally, they appear to act as pivotal regulators of many diseases, such as neurologic disorders, heart disease, vascular diseases, and particularly cancer [6] . MicroRNAs are aberrantly expressed in a variety of tumor types and regulate tumor biology by acting as oncogenes or tumor suppressors [7] . Recently, several studies have indicated that the expressions of microRNAs are linked to patients' survival, and they function as prognostic biomarkers [8, 9] .
Among the different microRNAs, miR-155 is regarded as important due to the significant differences in its expression in a variety of tumors including prostate cancer, esophageal cancer, leukemia, and non-small cell lung cancer [10] [11] [12] [13] . Based on some laboratory studies, the overexpression of miR-155 is associated with high proliferation, low apoptosis, and high invasion of tumors [14, 15] . Lately, some prognostic studies have shown elevated levels of miR-155 in gliomas, with a higher miR-155 expression associated with worse outcomes [16, 17] . However, only a few studies to date have focused on the prognostic role of miR-155 expression in gliomas, revealing controversial findings. Most of these studies found high miR-155 expression in glioma tissues to correlate with poor survival, while others were unable to confirm these results [18] .
Since published studies have had small sample sizes, it is necessary to carry out an integrated meta-analysis of the publications to identify the This research, up to the moment of writing this manuscript, is the first meta-analysis to explore the potential prognostic value of miR-155 in glioma patients. Only non-laboratory studies were considered for the analysis. The investigation also provides more theoretical backings to a new treatment argument for a later research.
Materials and methods

Search strategy
We performed a complete search for available literature in the electronic databases of Pubmed, Embase, Cochrane Library, China National Knowledge Infrastructure, and Google Scholar until April 2018, using the following words "(miR-155 OR miRNA-155 OR miR155 OR microRNA-155) AND (glioma OR glioblastoma OR CNS cancer OR glial cell tumor OR astrocytoma)." References in eligible studies were also screened to identify potentially related articles. We also contacted some authors when the crucial data were not reported in their original papers. Two authors completed this procedure independently and resolved any discrepancy through the consensus with a third reviewer.
Selection criteria
Inclusion criteria were as follows: 1) studies focusing on glioma and glioblastoma patients; 2) studies exploring the link between miR-155 expression and cancer prognosis; and 3) studies providing HR directly or key information to calculate HR indirectly, such as Kaplan-Meier curves and original prognostic data. Studies were excluded if they were either: a) reviews, letters, or laboratory studies; or b) studies that have overlapping or duplicate data.
Qualitative assessment
The quality of the studies selected was assessed independently by two authors using the modified Newcastle-Ottawa scale (NOS) [19] . The scale consisted of three aspects: selection (0-4 points), comparability (0-2 points), and outcomes (0-3 points); the full score was 9 points. Studies with more than 6 points were considered as high quality studies.
Data extraction
The following details were recorded for each enrolled study: first author's name, publication year, country, tumor grade, sample size, test method to assay miR-155 levels, the cutoff value to determine high or low expression of miR-155, sample sources, follow-up time, extraction method of HR, outcome and NOS. Directly extracted HR values were
reported, while Kaplan-Meier curves were used to extract indirect HR values via the described method [20] . We preferred extracting HRs and 95%CIs from the multivariate analysis if both multivariate analysis and univariate analysis of the results were performed.
Statistical analysis
HRs and 95%CIs were used to measure the effect size. The heterogeneity of the studies included in this meta-analysis was assessed by the I 2 statistic test. We used the random effects model to minimize the influence of heterogeneity while I 2 >50% or P<0.10 [21] , otherwise, the fixed effects model was selected. Subgroup analyses were applied to identify the sources of any observed heterogeneity. Publication bias was examined using the Begg's funnel plot, Begg's test, and Egger's test. P<0.05 was considered significant [22] . All analyses were performed by using software STATA version 12.0 and Engauge Digitizer version 4.1.
Result
Literature research
A total of 96 studies were retrieved from the initial search. After 
Characteristics of included studies
The main characteristics of the 6 included articles are shown in Table 1 .
All of them were published in recent years and were from 3 different countries. One of the selected articles separately assessed the prognostic value of miR-155-5p and miR-155-3p, two key derivatives of miR-155, with different prognosis data [18] . Another article analyzed three separate batches downloaded from TCGA datasets which reported findings on a group of patients with gliomas of GBM, WHO Ⅲ, and WHOⅠ-Ⅳ [25] .
There was no overlap between the batches enrolled in the article. Thus, 9 studies (from 6 articles) involving 1259 patients were available for this meta-analysis. Four studies examined glioblastoma, two investigated glioma with grade Ⅲ, and the remaining two involved glioma with different grades. Microarray (n = 2) and q-PCR (n = 3) were used to All studies provided data on OS, while only 2 studies provided findings on PFS with respect to outcomes.
Correlation of miR-155 expression with OS and PFS in gliomas
A total of nine studies were used for OS analysis (I 2 = 52.4%, P = 0.032) Furthermore, sensitivity analysis did not indicate alterations in the results (HR) by sequentially eliminating individual studies, suggesting that no single study significantly contributed to the heterogeneity for OS (Fig 3) . As two [23, 24] of the nine studies provided progression-free survival-related data, a meta-analysis of PFS was conducted using the random-effects model (Fig 2) . However, no significant HR (HR = 1.82, 95%CI [0.78-4.27], P = 0.167) and high heterogeneity were found (I 2 = 92.2%, P<0.001). As a result, we did not perform the sub-group analysis of PFS and miR-155. Despite the lack of significant differences, a similar correlated trend was observed for PFS and miR-155.
Subgroup analysis
Given that the substantial heterogeneity exhibited in the studies with respect to the OS, we performed subgroup analysis to explore the heterogeneity of covariates including country, tumor grade, test method, cutoff, extraction method, and multivariate analysis ( 
Publication bias
Finally, publication bias in our study of OS was assessed using the Begg's funnel plots, Egger's test, and Begg's test. Although the funnel plot revealed a substantial publication bias (Fig 4) , the P-value of Begg's and
Egger's tests were 0.348 and 0.167, respectively, suggesting that there was no significant publication bias in the entire study. 
Discussion
In previous studies, patients with differing miRNA expressions had Wu et al. [18] reported that there was no significant association between miR-155-5p expression and OS in glioma patients. In light of these inconsistent results on the prognostic value of miR-155 in gliomas, a comprehensive study is highly needed.
Summary and explanation of the main results
In this meta-analysis, our quantitative results strongly supported the studies, and others, from the remaining studies, were directly reported, but no obvious heterogeneity was shown in the two subgroups ( Table 2 ), implying that the data extracted from K-M survival curves were reliable.
Limitations of the study
Several important limitations should be considered when interpreting our analysis. Firstly, in order to get a more comprehensive result, we pooled HRs for both OS and PFS. However, further analysis for PFS and
miR-155 was not conducted for only two eligible studies. Secondly, to date, few studies have analyzed the prognostic value of miR-155 in LGG (Lower Grade Glioma) patients. Barbano et al. [25] showed that miR-155 had a significant higher expression level in grade III+IV than in grade II, but none of the miRNAs they had selected was associated with prognosis in grade II gliomas from the LGG dataset (n = 57). Reports from Wu et al.
[18] and Sun et al. [23] present miR-155 as being significantly associated with tumor grade with their expression levels higher in GBM than in
LGG. However, both these studies lacked prognostic data. Therefore, we cannot investigate the differences of overall survival between WHO I and IV glioma patients and must recommend that further investigations are performed. Thirdly, Wu et al. [18] reported that the MIR155 host gene (MIR155HG) encoding miR-155 correlated with the overall survival in gliomas (HR = 2.082, P = 0.023) and Schliesser et al. [17] found that miR-155 promoter methylation and miR-155 expression correlated negatively, with the methylation, in particular, showing superior correlation with patient survival. However, due to limited data, we were unable to perform meta-analysis on the relationship between these miR-155 associated parameters and prognosis in glioma patients.
Moreover, only one [18] of the selected articles studied the derivatives of miR-155. Additionally, it difficult to define the standard cutoff value; most studies used the median value as the expression cutoff, and there
was no consensus between these values among the studies selected.
Finally, although subgroup analysis was performed, heterogeneity still existed in some groups, and we could hardly explain its source.
Conclusion
In summary, our meta-analysis suggests that miR-155 has a prognostic value in glioma patients. In view of the limitation of the current analysis, our findings should be interpreted with caution. Further large-scale, well-designed, and multi-center prospective studies should be conducted to elucidate the exhaustive mechanism of miR-155 overexpression in human glioma and the relationship with poor prognosis. A C C E P T E D M A N U S C R I P A C C E P T E D M A N U S C R I P T
